{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:46:34Z","timestamp":1783766794637,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012360","name":"Heart of England NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015846","name":"Llywodraeth Cymru","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015846","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C7852\\u2013A25447"],"award-info":[{"award-number":["C7852\\u2013A25447"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C8225\/A21133"],"award-info":[{"award-number":["C8225\/A21133"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejca.2024.114309","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T22:11:08Z","timestamp":1726351868000},"page":"114309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data"],"prefix":"10.1016","volume":"211","author":[{"given":"Melissa Ruth","family":"Gannon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dodwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibby","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Alan","family":"Cromwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.ejca.2024.114309_bib1","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114309_bib2","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"4","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2024.114309_bib3","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol: J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2024.114309_bib4","unstructured":"NICE. Early and locally advanced breast cancer: diagnosis and management. 2018. Available from: \u3008www.nice.org.uk\/guidance\/ng101\u3009."},{"issue":"20","key":"10.1016\/j.ejca.2024.114309_bib5","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2016.67.0182","volume":"34","author":"Denduluri","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114309_bib6","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1016\/S1470-2045(11)70383-7","article-title":"Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)","volume":"13","author":"Biganzoli","year":"2012","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2024.114309_bib7","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.2018.79.2697","article-title":"Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO Clinical Practice Guideline Update","volume":"36","author":"Giordano","year":"2018","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114309_bib8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials","volume":"22","author":"Early Breast Cancer Trialists' Collaborative g","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114309_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.critrevonc.2010.01.002","article-title":"The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer","volume":"76","author":"Ring","year":"2010","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114309_bib10","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/sj.bjc.6603709","article-title":"Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years","volume":"96","author":"Lavelle","year":"2007","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2024.114309_bib11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jgo.2020.01.005","article-title":"Initiation of adjuvant chemotherapy and trastuzumab for human epidermal growth receptor 2-positive early invasive breast cancer in a population-based cohort study of older women in England","volume":"11","author":"Gannon","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114309_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clbc.2011.03.001","article-title":"Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era","volume":"11","author":"Palmieri","year":"2011","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.114309_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/bjc.2011.506","article-title":"Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?","volume":"106","author":"Webster","year":"2012","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2024.114309_bib14","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10.1016\/j.ejca.2024.114309_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The reporting of studies conducted using observational routinely-collected health data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2024.114309_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hernan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2024.114309_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djad092","article-title":"Target trial emulation to assess real-world efficacy in the ESME metastatic breast cancer cohort","author":"Antoine","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ejca.2024.114309_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz076","article-title":"Data resource profile: National Cancer Registration Dataset in England","volume":"49","author":"Henson","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114309_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyx015","article-title":"Data resource profile: hospital episode statistics admitted patient care (HES APC)","volume":"46","author":"Herbert","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114309_bib20","article-title":"Data resource profile: the systemic anti-cancer therapy (SACT) dataset","volume":"49","author":"Bright","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"7","key":"10.1016\/j.ejca.2024.114309_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020980","article-title":"Cohort profile: prescriptions dispensed in the community linked to the national cancer registry in England","volume":"8","author":"Henson","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2024.114309_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2023.102337","article-title":"Concordance of cancer drug therapy information derived from routinely collected hospital admissions data and the Systemic Anti-Cancer Therapy (SACT) dataset, for older women diagnosed with early invasive breast cancer in England","volume":"83","author":"Gannon","year":"2023","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114309_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035395","article-title":"Construction of the secondary care administrative records frailty (SCARF) index and validation on older women with operable invasive breast cancer in England and Wales: a cohort study","volume":"10","author":"Jauhari","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.ejca.2024.114309_bib24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"10.1016\/j.ejca.2024.114309_bib25","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.ejca.2024.114309_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"issue":"25","key":"10.1016\/j.ejca.2024.114309_bib27","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"28","key":"10.1016\/j.ejca.2024.114309_bib28","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.ejca.2024.114309_bib29","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-019-0612-5","article-title":"Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016)","volume":"121","author":"Tang","year":"2019","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2024.114309_bib30","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1634\/theoncologist.2015-0006","article-title":"Real-life use and effectiveness of adjuvant trastuzumab in early breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium","volume":"20","author":"Seferina","year":"2015","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ejca.2024.114309_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1634\/theoncologist.2016-0193","article-title":"Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany","volume":"22","author":"Dall","year":"2017","journal-title":"Oncologist"},{"issue":"33","key":"10.1016\/j.ejca.2024.114309_bib32","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2024.114309_bib33","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2024.114309_bib34","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jgo.2015.06.003","article-title":"Trastuzumab in the treatment of elderly patients with early breast cancer: results from an observational study in Germany","volume":"6","author":"Dall","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114309_bib35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.breast.2014.05.022","article-title":"Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice","volume":"23","author":"Bonifazi","year":"2014","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.ejca.2024.114309_bib36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(11)70033-X","article-title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial","volume":"12","author":"Gianni","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114309_bib37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10549-016-3878-9","article-title":"The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer","volume":"158","author":"van Ramshorst","year":"2016","journal-title":"Breast Cancer Res Treat"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924009651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924009651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T19:44:49Z","timestamp":1728071089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924009651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":37,"alternative-id":["S0959804924009651"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114309","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114309"}}